Regulatory Disclosure Update
Jubilant Pharmova Limited (Scrip Code: 530019, Symbol: JUBLPHARMA) has disclosed an update regarding the USFDA inspection of its contract manufacturing facility.
Key Event Details
- Previous Disclosure Reference: Continuation of disclosure dated June 19, 2026
- Communication Receipt Date: September 10, 2026, at 10:52 AM PST (11:22 PM IST)
- Regulatory Outcome: USFDA has classified the facility as "Voluntary Action Indicated (VAI)"
- Inspection Period: June 8, 2026, to June 17, 2026
- Document Reviewed: Establishment Inspection Report (EIR)
Corporate Structure
Jubilant HollisterStier LLC is identified as a subsidiary of Jubilant Pharma Holding Inc., which is itself a subsidiary of Jubilant Pharma Limited, Singapore. Jubilant Pharma Limited, Singapore is a wholly owned subsidiary of Jubilant Pharmova Limited.
Facility Operations
The Spokane facility is described as a leading integrated contract manufacturer of:
- Sterile injectables (both liquid and lyophilization)
- Ophthalmics (ointment, liquid and creams)
The facility provides specialized manufacturing services for pharmaceutical and biopharmaceutical industries, including full range support from process qualifications through commercial release.
Company Background
Jubilant Pharmova Limited is described as an integrated global pharmaceutical company engaged in multiple businesses:
- Radiopharma (with 45 radiopharmacies in the USA)
- Allergy Immunotherapy
- Contract Development and Manufacturing of sterile injectables
- Contract Research Development and Manufacturing
- Generics
- Proprietary Novel Drugs
The company employs approximately 5,500 people globally and serves customers across over 75 countries.